Biogen Inc
BIIB
View Detailed Chart
187.620USD
+1.620+0.87%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
27.52BMarket Cap
17.07P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.87%
5 Days
+5.51%
1 Month
+5.67%
6 Months
+38.64%
Year to Date
+6.61%
1 Year
+26.07%
View Detailed Chart
TradingKey Stock Score of Biogen Inc
Currency: USD Updated: 2026-01-09Key Insights
Biogen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 7 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 181.86.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biogen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Biogen Inc Highlights
StrengthsRisks
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Fairly Valued
The company’s latest PE is 17.07, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 137.76M shares, decreasing 4.66% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 2.30K shares of this stock.
Analyst Rating
Based on
36
analysts
Buy
Current Rating
181.857
Target Price
+4.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Biogen Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biogen Inc Info
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Ticker SymbolBIIB
CompanyBiogen Inc
CEOViehbacher (Christopher A)
Websitehttps://www.biogen.com/
FAQs
What is the current price of Biogen Inc (BIIB)?
The current price of Biogen Inc (BIIB) is 187.620.
What is the symbol of Biogen Inc?
The ticker symbol of Biogen Inc is BIIB.
What is the 52-week high of Biogen Inc?
The 52-week high of Biogen Inc is 190.200.
What is the 52-week low of Biogen Inc?
The 52-week low of Biogen Inc is 110.035.
What is the market capitalization of Biogen Inc?
The market capitalization of Biogen Inc is 27.52B.
What is the net income of Biogen Inc?
The net income of Biogen Inc is 1.63B.
Is Biogen Inc (BIIB) currently rated as Buy, Hold, or Sell?
According to analysts, Biogen Inc (BIIB) has an overall rating of Buy, with a price target of 181.857.
What is the Earnings Per Share (EPS TTM) of Biogen Inc (BIIB)?
The Earnings Per Share (EPS TTM) of Biogen Inc (BIIB) is 10.991.
Related Instruments
-1.99%
-0.66%
-1.74%
+0.68%
-0.43%
+0.06%
+2.56%
-1.21%
+0.36%
+0.75%
+1.87%
-1.24%
-0.07%
+0.34%
+0.18%
-1.29%
-0.56%
0.00%
+0.25%
-0.28%Popular Symbols
